SEC Form 4 · accession 0001193125-26-328467
Inhibikase Therapeutics, Inc. · IKT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis N Berman
Director
Period of report
Jul 30, 2026
Accepted (ET)
Jul 31, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001750149
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 30, 2026 | M | 21,854 | $1.26 | A | 21,854 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.26 | Jul 30, 2026 | M | 21,854 | D | — | Aug 31, 2026 | Common Stock | 21,854 | 0 | D |
Explanation of responses
- F1The options are fully vested and exercisable.